Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -9 of 9 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				Pharmaceutical / Industry				20040135 NCT00089661


2.		AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				Pharmaceutical / Industry				20040138 HALT, NCT00089674


3.		Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				20050147 NCT00286091


4.		A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				20050136 NCT00321464


5.		Double-Blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				20050244 NCT00330759


6.		AMG 162 in Bisphosphonate Naive Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				20040113 NCT00091832

Last Modified: 7/10/2007 First Published: 6/9/2006


7.		Phase II Study of Denosumab in Patients With Relapsed or Plateau-Phase Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				FHCRC-2082.00 AMGEN-20050134, NCT00259740


8.		Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				20050134 NCT00259740


9.		Safety and Efficacy Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of Bone

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				20040215 NCT00396279

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute